Blue Owl Capital Inc. Class A Common Stock vs UnitedHealth Group Inc — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.79 (market cap $6.35B), while UnitedHealth Group Inc trades at $395.85 (market cap $339.08B). The key difference: UnitedHealth Group Inc is far larger — about 53.4× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (9.8%). Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| OWL | UNH | |
|---|---|---|
Market Cap | $6.35B | $339.08B |
Volume | 15,716,423 | 12,648,635 |
Sector | Financials | Health |
52-Week High | $17.17 | $436.35 |
52-Week Low | $8.23 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $10.53B | $380.94B |
Dividend Yield | 9.8% | 2.46% |
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
UnitedHealth Group (UNH) trades at $378.52, down 0.21% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats in recent quarters, including Q3 2026 EPS of $4.69 beating expectations of $4.14. Revenue growth remains solid at $447.57B for 2025, though net margins have compressed to 3.14%. Recent developments include strategic moves with TPG for WellMed operations and continued AI investments in Optum Insight.
UNH presents a compelling investment case with 82.7% analyst buy ratings and a $470.11 consensus price target representing 24% upside. The company's Medicare Advantage strength and Optum improvements support growth, though regulatory scrutiny and medical cost pressures remain key risks. Strong institutional ownership and Michael Burry's recent call option position signal confidence in the turnaround story.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →